CL2021003438A1 - Sales de un compuesto, formas cristalinas de las sales y método de preparación y uso de las mismas - Google Patents

Sales de un compuesto, formas cristalinas de las sales y método de preparación y uso de las mismas

Info

Publication number
CL2021003438A1
CL2021003438A1 CL2021003438A CL2021003438A CL2021003438A1 CL 2021003438 A1 CL2021003438 A1 CL 2021003438A1 CL 2021003438 A CL2021003438 A CL 2021003438A CL 2021003438 A CL2021003438 A CL 2021003438A CL 2021003438 A1 CL2021003438 A1 CL 2021003438A1
Authority
CL
Chile
Prior art keywords
salts
compound
preparation
crystal forms
fluoro
Prior art date
Application number
CL2021003438A
Other languages
English (en)
Spanish (es)
Inventor
Lei Yin
Zhenglin Yao
Original Assignee
Gan & Lee Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=74040655&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2021003438(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gan & Lee Pharmaceuticals Co Ltd filed Critical Gan & Lee Pharmaceuticals Co Ltd
Publication of CL2021003438A1 publication Critical patent/CL2021003438A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL2021003438A 2019-06-21 2021-12-21 Sales de un compuesto, formas cristalinas de las sales y método de preparación y uso de las mismas CL2021003438A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201910542355 2019-06-21

Publications (1)

Publication Number Publication Date
CL2021003438A1 true CL2021003438A1 (es) 2022-09-30

Family

ID=74040655

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021003438A CL2021003438A1 (es) 2019-06-21 2021-12-21 Sales de un compuesto, formas cristalinas de las sales y método de preparación y uso de las mismas

Country Status (16)

Country Link
US (1) US20220168302A1 (cg-RX-API-DMAC7.html)
EP (1) EP3988546A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022538076A (cg-RX-API-DMAC7.html)
KR (1) KR20220041090A (cg-RX-API-DMAC7.html)
CN (1) CN115708409B (cg-RX-API-DMAC7.html)
AR (1) AR119184A1 (cg-RX-API-DMAC7.html)
AU (1) AU2020296048A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021025944A2 (cg-RX-API-DMAC7.html)
CA (1) CA3144546A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021003438A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022000502A2 (cg-RX-API-DMAC7.html)
IL (1) IL289231A (cg-RX-API-DMAC7.html)
MX (1) MX2022000051A (cg-RX-API-DMAC7.html)
PH (1) PH12021553151A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020253875A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202200964B (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116113628B (zh) * 2020-08-31 2026-07-17 甘李药业山东有限公司 一种含cdk4/6抑制剂的药物组合物
WO2022242563A1 (zh) * 2021-05-17 2022-11-24 甘李药业股份有限公司 一种cdk4/6抑制剂的医药用途
WO2024208265A1 (zh) * 2023-04-04 2024-10-10 苏州开拓药业股份有限公司 具有刺猬通路拮抗剂活性手性杂环化合物的盐型及其晶型

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL150524A0 (en) * 2000-01-07 2003-02-12 Transform Pharmaceuticals Inc High-throughput formation, identification, and analysis of diverse solid-forms
CN106810536A (zh) 2015-11-30 2017-06-09 甘李药业股份有限公司 一种蛋白激酶抑制剂及其制备方法和医药用途

Also Published As

Publication number Publication date
WO2020253875A1 (zh) 2020-12-24
EP3988546A4 (en) 2023-05-17
EP3988546A1 (en) 2022-04-27
KR20220041090A (ko) 2022-03-31
JP2022538076A (ja) 2022-08-31
US20220168302A1 (en) 2022-06-02
CN115708409B (zh) 2026-08-07
BR112021025944A2 (pt) 2022-02-08
PH12021553151A1 (en) 2022-07-25
IL289231A (en) 2022-02-01
CN115708409A (zh) 2023-02-21
CA3144546A1 (en) 2020-12-24
AR119184A1 (es) 2021-12-01
MX2022000051A (es) 2022-05-24
CO2022000502A2 (es) 2022-01-28
ZA202200964B (en) 2022-08-31
AU2020296048A1 (en) 2022-02-10

Similar Documents

Publication Publication Date Title
MX2022001421A (es) Compuesto tetracíclico, método de preparación y uso del mismo.
BR112022005193A2 (pt) Composto de piridona fundido, método de preparação do mesmo e uso do mesmo
CL2019000477A1 (es) Un esteroide 19 nor-c21-n-pirazolilo c3,3- disustituido cristalino.
CO2022002634A2 (es) Formas cristalinas de moduladores del cftr
ECSP078030A (es) Formas cristalinas y otras formas de las sales de ácido láctico de 4-amino-5-fluoro-3-[6-(4-metilpiperazin -1-il)-1h-bencimidazol-2 -il]-1h-quinolin-2-ona
CO2020016285A2 (es) Compuestos heterocíclicos y de heteroarilo para tratar la enfermedad de huntington
AR035573A1 (es) Profarmacos de pirimidinas inhibitorias de la replicacion de hiv
CO2020013564A2 (es) Compuestos heteroaril tetracíclicos
CR20200553A (es) Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos
UY26454A1 (es) Cristal de 4-carboxamino-1,2,3,4-tetrahidroquinolina 2-sustituida
PE20191496A1 (es) 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas
AR095192A1 (es) Quinolina y quinazolinamidas como modulares de canales de sodio
MX355428B (es) Formas cristalinas del acido [ (4-hidroxi-1-metil-7-fenoxi-isoquin olin-3-carbonil) -amino] -acetico inhibidor de prolil hidroxilasa.
UY28514A1 (es) Nuevos compuestos
DK3986561T3 (da) Pyrido[2,3-D]pyrimidin-derivater som inhibitorer af replikationen af human immundefektvirus
CO2022000502A2 (es) Sales de un compuesto, formas cristalinas de las sales y método de preparación y uso de las mismas
SA520411638B1 (ar) Tam أملاح لمشتقات بيرولو ترايازين مفيدة كمثبطات لـ
AR041271A1 (es) Quinazolinonas espirocondensadas y su uso como inhibidores de la fosfodiesterasa
UY30409A1 (es) Pirazolopiridinas sustituidas y sus sales, composiciones farmaceuticas que las comprenden, metodos para prepararlas y sus usos.
AR045388A1 (es) Inhibidores del c-kit imidazopiridinicos n3-sustituidos
MX377489B (es) Compuesto de pirazolo[1,5-a]pirimidina.
CL2019002321A1 (es) Procesos para preparar ag-10, sus intermediarios, y sales de los mismos.
AR078164A1 (es) Derivados de isoxazolidina, proceso para preparar dichos compuestos y composiciones farmaceuticas que los comprenden
CO2021004873A2 (es) Inhibidores de o-glicoproteína-2-acetamido-2-desoxi-3-d-glucopiranosidasa
MX2019011931A (es) Formas cristalinas de (s)-afoxolaner.